US FDA Approves Marketing of Biomove 3000 for Stroke Rehabilitation. The Highly Affordable Home Therapy System Enters U.S Market

US FDA approves marketing of the highly affordable and easy to use Home Stroke Therapy device Biomove 3000 http://www.biomove.com manufactured by the Israeli company Curatronic Ltd.

(PRWEB) March 15, 2005 -- Hashmonaim, Israel --- Curatronic Ltd. announced today that it has obtained U.S. Food and Drug Administration (FDA) marketing approval for the Biomove 3000 Stroke Rehabilitation system.

The Biomove 3000 system was specifically developed for home therapy following a stroke. The highly affordable battery-powered device detects extremely small electrical EMG signals that persist in paralyzed muscles after a stroke and uses these tiny signals to initiate an electrical stimulation impulse to the muscles, resulting in actual muscle movement by the patient.

FDA 510(k) approval allows Biomove 3000 to be marketed in the United States, where over 700,000 individuals experience a stroke each year. Millions of people suffer from the debilitating effects of stroke. Fifty percent have some one-sided paralysis and seek effective treatment for their severe, long-term disabilities.

Ben Philipson, President of Curatronic Ltd. said, "We are delighted to have received FDA approval for the Biomove 3000 system, which enables us to reach the many stroke victims in the US market with our economical, easy-to-use system.

Further information about the Biomove 3000 system can be found at Curatronics Biomove web site: http://www.biomove.com

Curatronic Ltd. was founded in 2000 as a privately held R&D company dedicated to developing affordable, easy to use state-of-the-art stroke rehabilitation and therapy devices for use by patients at home and by professional therapists.

Curatronic Ltd.

P.O.Box 1532

Hashmonaim

73127 Israel

Tel: 011-972-8976-1441

Fax: 011-972-8976-2020

###